These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24072776)

  • 1. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
    Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
    Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
    Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
    AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy.
    Grignol VP; Smith AD; Shlapak D; Zhang X; Del Campo SM; Carson WE
    Surg Oncol; 2015 Dec; 24(4):353-8. PubMed ID: 26690825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
    Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
    Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
    Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
    Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
    Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
    Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
    Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
    Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
    Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
    Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
    Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.
    Silvestris N; Scartozzi M; Graziano G; Santini D; Lorusso V; Maiello E; Barni S; Cinieri S; Loupakis F; Pisconti S; Brunetti AE; Palasciano G; Palmieri VO; Del Prete M; Dell'Aquila E; Latiano TP; Petrelli F; Lutrino S; Rossini D; Giampieri R; Lotesoriere C; Cascinu S
    Expert Opin Biol Ther; 2015 Feb; 15(2):155-62. PubMed ID: 25411089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
    Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
    PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy.
    Schraag A; Klumpp B; Afat S; Gatidis S; Nikolaou K; Eigentler TK; Othman AE
    Eur J Radiol; 2019 Dec; 121():108688. PubMed ID: 31704599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
    Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
    Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension.
    Schuster C; Eikesdal HP; Puntervoll H; Geisler J; Geisler S; Heinrich D; Molven A; Lønning PE; Akslen LA; Straume O
    PLoS One; 2012; 7(6):e38364. PubMed ID: 22719881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
    Marmorino F; Salvatore L; Barbara C; Allegrini G; Antonuzzo L; Masi G; Loupakis F; Borelli B; Chiara S; Banzi MC; Miraglio E; Amoroso D; Dargenio F; Bonetti A; Martignetti A; Paris M; Tomcikova D; Boni L; Falcone A; Cremolini C
    Br J Cancer; 2017 Jan; 116(3):318-323. PubMed ID: 28081548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.
    Grignol VP; Olencki T; Relekar K; Taylor C; Kibler A; Kefauver C; Wei L; Walker MJ; Chen HX; Kendra K; Carson WE
    J Immunother; 2011; 34(6):509-15. PubMed ID: 21654521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
    Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
    J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.
    Basler L; Gabryś HS; Hogan SA; Pavic M; Bogowicz M; Vuong D; Tanadini-Lang S; Förster R; Kudura K; Huellner MW; Dummer R; Guckenberger M; Levesque MP
    Clin Cancer Res; 2020 Aug; 26(16):4414-4425. PubMed ID: 32253232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.